Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jan 26.

Published in final edited form as: ACS Nano. 2020 Dec 22;15(1):1608–1626. doi: 10.1021/acsnano.0c09206

Figure 6. — Pretreatment using epitope-encapsulating nanoparticles to assess the impact on OVA-induced serological responses and cytokine production in a transgenic OT-II murine model. Figure S4 outlines the experimental animal protocol. (A) Serum anti-OVA IgE and IgG₁ antibody titers were determined by ELISA. (B) TH2 cytokine (IL-4, IL-5, and IL-13) levels in the BALF, determined by ELISA. (C) Differential eosinophil, neutrophil, and macrophage cell counts on BALF. (D) TGF-β, IL-10 and INF-γ levels in the BALF, determined by ELISA. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA followed by a Tukey’s test).

Figure 6. — Pretreatment using epitope-encapsulating nanoparticles to assess the impact on OVA-induced serological responses and cytokine production in a transgenic OT-II murine model. Figure S4 outlines the experimental animal protocol. (A) Serum anti-OVA IgE and IgG₁ antibody titers were determined by ELISA. (B) TH2 cytokine (IL-4, IL-5, and IL-13) levels in the BALF, determined by ELISA. (C) Differential eosinophil, neutrophil, and macrophage cell counts on BALF. (D) TGF-β, IL-10 and INF-γ levels in the BALF, determined by ELISA. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA followed by a Tukey’s test).